#### The First Report on the Japanese CTO PCI Expert Registry

#### Etsuo Tsuchikane, MD, PhD

on behalf of Japanese Board of CTO Interventional Specialist

#### Japanese CTO-PCI Registry

Currently,

#### 'Retrograde Summit General Registry'

and

#### 'Japanese CTO PCI Expert Registry'

are being conducted in Japan.

#### **Japanese CTO PCI Expert Registry**

- The Japanese Board of CTO Interventional Specialists was established in 2013 to accumulate quantitative data to identify issues such as stagnation in the development of CTO-PCI techniques
- Starting from 2014, Japanese CTO PCI Expert Registry began establishing a database of CTO-PCI performed by certified expert physicians who have a certain level of CTO-PCI skills
- Patients are enrolled by certified expert operators.
  - Procedure success is adjudicated by a Corelab

#### **Registry Overview**

|                              | Retrograd   | le Summit           | Iananasa CTO PCI   |
|------------------------------|---|---------------------|--|
|                              | Registry  | General<br>Registry | Expert Registry  |
| Pts.<br>Enrollment           | Jan. 2009 ~<br>Dec. 2013  | Jan. 2014~          | Jan. 2014~   |
| Participants                 | 56 of   | 40 of               | 12 of Japanese Export physicians   |
| As of Jun. 2015              | Japanese  | Centers             | 42 of Japanese Expert physicians   |
| Criteria for<br>Participants | <ul> <li>Centers approved by<br/>Retrograde Summit</li> <li>Cases treated by Expert are<br/>excluded</li> </ul> |                     | <ul> <li>More than 300 cases of experience of CTO-PCI</li> <li>More than 50 cases of CTO-PCI per year</li> <li>Recommendation from two or more steering</li> </ul> |
|                              |   |                     | committee member   |
| Core lab                     | None  |                     | Adjudication of Indication and Procedure<br>Success  |
| Organization                 | Retrograd   | e Summit            | Japanese Board of CTO interventional specialist  |
| Chairman                     | Habara (ir<br>Tsuchi  | itiated by<br>kane) | Tsuchikane (initiated by Katoh, late Mitsudo)  |

## **Data Unification**

- The database for Retrograde Summit general registry has already been modified to collect same dataset as Japanese CTO PCI Expert Registry
  - The outcome from both Retrograde Summit General Registry and Japanese CTO PCI Expert Registry will be compared and reported in the near future

## **Features of Expert Registry**

- Officially started from January 2014, will end in December 2022
- All clinical data including patient background data and details of the procedures are input via an electronic capture system
- Pre-procedural CAG and CTA (optional), and procedural angiograms and IVUS images are sent as DICOM data to an independent core laboratory
- Annual clinical follow-up data are collected for 5 years (only in domestic pts)

#### **Patient Enrollment**



#### **The Initial Outcomes from**

#### Japanese CTO PCI Expert Registry

2014-2015

#### **Patient Enrollment**



## Definitions

- The procedure was defined here as bidirectional approach (BA) where an attempt was made to cross the collateral channel for retrograde revascularization techniques.
- Cases were divided into 3 groups based on ITT principle; primary antegrade approach (PAA), primary BA (PBA), and rescue BA (RBA).
- PAA included rescue BA and re-switched antegrade approach.
- No antegrade dissection and reentry device was used.

|                    | Overall   | PAA       | PBA           | PAA vs. PBA |
|--------------------|-----------|-----------|---------------|-------------|
|                    | N=2596    | N=1872    | N=724         | P-value     |
|                    |           | 72.1%     | 27.9%         |             |
| Age                | 66.9±10.9 | 66.8±10.9 | 66.9±10.7     | 0.863       |
| BMI                | 24.7±3.8  | 24.7±3.8  | 24.6±3.8      | 0.413       |
| LVEF               | 54.8±12.9 | 54.9±12.9 | 54.6±12.8     | 0.458       |
| eGFR               | 64.9±29.0 | 65.1±30.2 | 64.3±25.7     | 0.458       |
| Male gender, %     | 86.1      | 85.1      | 88.4          | 0.018       |
| Hypertension, %    | 78.5      | 78.0      | 80.8          | 0.12        |
| Dyslipidemia, %    | 77.5      | 76.1      | 82.1          | 0.001       |
| Diabetes, %        | 44.9      | 44.9      | 45.8          | 0.35        |
| Current smoking, % | 54.4      | 58.0      | 62.3          | 0.057       |
| OMI, %             | 51.0      | 51.7      | 51.3          | 0.895       |
| Prior CABG, %      | 7.9       | 7.4       | 9.4           | 0.105       |
| Prior PCI, %       | 63.2      | 61.8      | 67.5          | 0.007       |
| Reattempt, %       | 20.6      | 15.1      | 34.8          | < 0.0001    |
| Syntax score       | 15.9±8.6  | 16.0±8.4  | 15.6±8.9      | 0.062       |
| J-CTO score        | 2.0±1.1   | 1.9±1.1   | $2.4 \pm 1.1$ | < 0.0001    |
| Target vessel, %   |           |           |               | < 0.0001    |
| LAD                | 30.9      | 32.9      | 25.7          |             |
| LCX                | 17.1      | 20.4      | 8.6           |             |
| LMT                | 0.6       | 0.6       | 0.6           |             |
| RCA                | 51.5      | 46.2      | 65.2          |             |

|                              | Overall | PAA    | PBA   | PAA vs. PBA |
|------------------------------|---------|--------|-------|-------------|
|                              | N=2596  | N=1872 | N=724 | P-value     |
| In-stent occlusion, %        | 13.6    | 16.9   | 5.1   | < 0.0001    |
| Distal run off (<3.0mm), %   | 65.0    | 64.9   | 67.2  | 0.274       |
| CTO length (≥20mm), %        | 60.5    | 57.0   | 69.6  | < 0.0001    |
| Side branch at proximal cap, | I       |        |       |             |
| %                            | 34.1    | 34.8   | 32.0  | 0.181       |
| Collateral filling, %        |         |        |       | < 0.0001    |
| Contralateral                | 50.7    | 47.6   | 58.8  |             |
| Ipsilateral                  | 13.3    | 15.9   | 6.6   |             |
| Both                         | 35.2    | 35.5   | 34.4  |             |
| None                         | 0.7     | 1.0    | 0.1   |             |
| Lesion calcification, %      | 52.3    | 50.5   | 56.9  | 0.003       |
| Proximal tortuosity, %       | 50.7    | 49.1   | 49.3  | 0.108       |
| Tortuosity of CTO lesion, %  | 24.6    | 21.6   | 32.5  | < 0.0001    |
| Morphology of proximal cap,  | l       |        |       |             |
| %                            |         |        |       | 0.002       |
| Blunt                        | 23.7    | 23.6   | 23.9  |             |
| No stump                     | 19.1    | 17.7   | 22.7  |             |
| Tapered/tunnel               | 56.7    | 58.3   | 52.3  | J           |

|                           | Overall     | PAA         | PBA         | PAA vs. PBA |
|---------------------------|-------------|-------------|-------------|-------------|
|                           | N=2596      | N=1872      | N=724       | P-value     |
| GW success, %             | 92.0        | 92.9        | 90.1        | 0.016       |
| Technical success, %      | 89.9        | 91.0        | 87.3        | 0.006       |
| Procedural success, %     | 88.8        | 90.3        | 85.0        | < 0.0001    |
| <b>Procedure time</b>     | 160.4±89.6  | 143.8±81.9  | 201.5±94.4  | < 0.0001    |
| Contrast volume           | 230.8±105.9 | 224.7±104.5 | 245.8±108.0 | < 0.0001    |
| In hospital death, %      | 0.2         | 0.2         | 0.4         | 0.362       |
| <b>MI, %</b>              | 1.2         | 0.8         | 2.0         | 0.018       |
| Acute stent thrombosis, % | 0.2         | 0.2         | 0.1         | 1.000       |
| Stroke, %                 | 0.2         | 0.2         | 0.3         | 0.628       |
| Emergent CABG, %          | 0           | 0           | 0           |             |
| <b>Emergent PCI</b>       | 0.2         | 0.2         | 0.1         | 1.000       |
| Coronary embolism, %      | 0.2         | 0.1         | 0.6         | 0.06        |
| Coronary perforation      |             |             |             |             |
| (tamponade), %            | 0.4         | 0.2         | 0.9         | < 0.0001    |
| Complications of puncture |             |             |             |             |
| site, %                   | 1.3         | 1.2         | 1.4         | 0.844       |
| CIN, %                    | 1.7         | 1.2         | 3.1         | 0.031       |

# **Primary Antegrade**



|                    | Antegrade alone | RBA             | Ant vs. RBA |
|--------------------|-----------------|-----------------|-------------|
|                    | N=1390          | N=482           | P-value     |
| Age                | 67.1±11.0       | 66.2±10.8       | 0.171       |
| BMI                | 24.6±3.7        | 24.8±3.9        | 0.370       |
| LVEF               | 55.0±13.0       | 54.6±12.8       | 0.434       |
| eGFR               | 64.5±30.8       | 66.6±28.4       | 0.277       |
| Male gender, %     | 84.1            | 88.2            | 0.031       |
| Hypertension, %    | 77.6            | 78.0            | 0.784       |
| Dyslipidemia, %    | 75.2            | 77.8            | 0.166       |
| Diabetes, %        | 44.7            | 44.5            | 0.434       |
| Current smoking, % | 51.9            | 57.1            | 0.137       |
| OMI, %             | 49.7            | 55.0            | 0.120       |
| Prior CABG, %      | 6.6             | 9.6             | 0.096       |
| Prior PCI, %       | 59.9            | 65.5            | 0.025       |
| Syntax score       | <u>16.1±8.5</u> | <u>15.8±8.1</u> | 0.797       |
| J-CTO score        | 1.7±1.1         | $2.2 \pm 1.1$   | < 0.0001    |
| Target vessel, %   |                 |                 | < 0.0001    |
| LAD                | 33.9            | 29.9            |             |
| LCX                | 22.9            | 13.3            |             |
| LMT                | 0.6             | 0.4             |             |
| RCA                | 42.6            | 56.4            |             |

|                                | Antegrade alone | RBA   | Ant vs. RBA |
|--------------------------------|-----------------|-------|-------------|
|                                | N=1390          | N=482 | P-value     |
| Reattempt, %                   | 12.7            | 22.2  | < 0.0001    |
| In-stent occlusion, %          | 20.2            | 7.3   | < 0.0001    |
| Distal run off (<3.0mm), %     | 64.2            | 65.1  | 0.762       |
| CTO length (≥20mm), %          | 53.5            | 67.2  | < 0.0001    |
| Side branch at proximal cap, % | 35.5            | 33.0  | 0.325       |
| Collateral filling, %          |                 |       | < 0.0001    |
| Contralateral                  | 46.6            | 50.4  |             |
| Ipsilateral                    | 18.4            | 8.9   |             |
| Both                           | 33.8            | 40.5  |             |
| None                           | 1.2             | 0.2   |             |
| Lesion calcification, %        | 48.8            | 55.4  | 0.013       |
| Proximal tortuosity, %         | 49.2            | 49.0  | 0.836       |
| Tortuosity of CTO lesion, %    | 18.7            | 29.9  | < 0.0001    |
| Morphology of proximal cap, %  |                 |       | 0.008       |
| Blunt                          | 24.6            | 20.7  |             |
| No stump                       | 16.0            | 22.6  |             |
| Tapered/tunnel                 | 59.1            | 56.2  |             |

# **Primary Antegrade**



# **Parallel Wiring and IVUS Guidance**



## **Primary Bidirectional**



# **Parallel Wiring and IVUS Guidance**



|                    | RBA       | PBA       | <b>RBA vs. PBA</b> |
|--------------------|-----------|-----------|--------------------|
|                    | N=482     | N=724     | P-value            |
| Age                | 66.2±10.8 | 66.9±10.7 | 0.289              |
| BMI                | 24.8±3.9  | 24.6±3.8  | 0.227              |
| LVEF               | 54.6±12.8 | 54.6±12.9 | 0.982              |
| eGFR               | 66.6±28.4 | 64.3±25.7 | 0.286              |
| Male gender, %     | 88.2      | 88.4      | 0.927              |
| Hypertension, %    | 78.0      | 80.5      | 0.449              |
| Dyslipidemia, %    | 77.8      | 81.9      | 0.175              |
| Diabetes, %        | 44.5      | 45.5      | 0.906              |
| Current smoking, % | 57.1      | 57.4      | 0.915              |
| <b>OMI, %</b>      | 55.0      | 50.8      | 0.320              |
| Prior CABG, %      | 9.6       | 9.4       | 0.972              |
| Prior PCI, %       | 66.5      | 67.2      | 0.948              |
| Syntax score       | 15.8±8.1  | 15.6±8.9  | 0.182              |
| J-CTO score        | 2.2±1.1   | 2.4±1.1   | 0.001              |
| Target vessel, %   |           |           | 0.007              |
| LAD                | 29.9      | 25.7      |                    |
| LCX                | 13.3      | 8.6       |                    |
| LMT                | 0.4       | 0.5       |                    |
| RCA                | 56.4      | 65.2      |                    |

|                                | RBA   | PBA   | <b>RBA vs. PBA</b> |
|--------------------------------|-------|-------|--------------------|
|                                | N=482 | N=724 | P-value            |
| Reattempt, %                   | 22.2  | 34.8  | < 0.0001           |
| In-stent occlusion, %          | 7.3   | 5.1   | 0.137              |
| Distal run off (<3.0mm), %     | 65.1  | 66.4  | 0.793              |
| CTO length (≥20mm), %          | 67.2  | 69.6  | 0.729              |
| Side branch at proximal cap, % | 33.0  | 32.0  | 0.754              |
| Lesion calcification, %        | 55.4  | 56.9  | 0.635              |
| Proximal tortuosity, %         | 49.0  | 49.3  | 0.401              |
| Tortuosity of CTO lesion, %    | 29.9  | 32.5  | 0.644              |
| Morphology of proximal cap, %  |       |       | 0.303              |
| Blunt                          | 20.7  | 23.9  |                    |
| No stump                       | 22.6  | 22.7  |                    |
| Tapered/tunnel                 | 56.2  | 52.3  |                    |
| Collateral used, %             |       |       | 0.801              |
| Sepal                          | 66.3  | 69.0  |                    |
| Epicardial                     | 24.7  | 23.4  |                    |
| Arterial                       | 6.4   | 5.2   |                    |
| Graft                          | 2.7   | 2.4   |                    |

|  | RBA         | PBA         | <b>RBA vs. PBA</b> |
|--|-------------|-------------|--------------------|
| _  | N=482       | N=724       | P-value            |
| Failed collateral crossing, %            | 20.2        | 16.0        | 0.062              |
| GW success, %                            | 80.3        | 90.1        | < 0.0001           |
| Technical success, %                     | 78.0        | 87.3        | < 0.0001           |
| Procedural success, %                    | 76.5        | 85.0        | < 0.0001           |
| Procedure time                           | 218.0±79.8  | 201.5±94.4  | < 0.0001           |
| Contrast volume                          | 279.5±123.9 | 245.8±108.0 | < 0.0001           |
| In hospital death, %                     | 0           | 0.4         | 0.296              |
| <b>MI, %</b>                             | 1.4         | 2.0         | 0.688              |
| Acute stent thrombosis, %                | 0           | 0.1         | 1.000              |
| Stroke, %                                | 0.7         | 0.3         | 0.370              |
| Emergent CABG, %                         | 0           | 0           |                    |
| <b>Emergent PCI</b>                      | 0.2         | 0.1         | 1.000              |
| Coronary embolism, %                     | 0           | 0.6         | 0.171              |
| Coronary perforation (tamponade), %      | 0.4         | 0.9         | 0.295              |
| <b>Complications of puncture site, %</b> | 1.2         | 1.4         | 0.796              |
| CIN, %                                   | 2.4         | 3.1         | 0.72               |

## **Predictors of Failure in PBA**

| PBA                         |               |             |          |  |  |  |
|-----------------------------|---------------|-------------|----------|--|--|--|
| Univariate analysis         |               |             |          |  |  |  |
|                             | OR CI P-value |             |          |  |  |  |
| Prior CABG                  | 1.87          | 1.024-3.416 | 0.042    |  |  |  |
| Dyslipidemia                | 0.565         | 0.349-0.915 | 0.02     |  |  |  |
| Side branch at proximal cap | 2.086         | 1.373-3.167 | 0.001    |  |  |  |
| Tortuosity of CTO           | 1.813         | 1.191-2.760 | 0.006    |  |  |  |
| Severe lesion calcification | 2.876         | 1.622-5.101 | < 0.0001 |  |  |  |
|                             |               |             |          |  |  |  |
|                             |               |             |          |  |  |  |
|                             |               |             |          |  |  |  |
| multi                       | variate analy | vsis        |          |  |  |  |
|                             | OR            | CI          | p-value  |  |  |  |
| Severe lesion calcification | 3.264         | 1.739-6.125 | < 0.0001 |  |  |  |
| Tortuosity of CTO           | 1.699         | 1.075-2.686 | 0.023    |  |  |  |
| Side branch at proximal cap | 2.399         | 1.524-3.776 | < 0.0001 |  |  |  |
| Dyslipidemia                | 0.535         | 0.322-0.889 | 0.016    |  |  |  |

## **Predictors of Failure in RBA**

| RBA                         |                     |             |          |  |  |  |
|-----------------------------|---------------------|-------------|----------|--|--|--|
| Uni                         | Univariate analysis |             |          |  |  |  |
|                             | OR                  | CI          | P-value  |  |  |  |
| Sex                         | 0.328               | 0.180-0.598 | < 0.001  |  |  |  |
| BMI                         | 1.604               | 1.024-2.511 | 0.039    |  |  |  |
| Diabetes                    | 1.720               | 1.097-2.698 | 0.018    |  |  |  |
| eGFR<60                     | 0.630               | 0.401-0.988 | 0.044    |  |  |  |
| <b>In-stent occlusion</b>   | 2.780               | 1.329-5.814 | 0.007    |  |  |  |
| Lesion>20mm                 | 1.722               | 1.039-2.855 | 0.035    |  |  |  |
| Tortuosity of CTO           | 1.734               | 1.087-2.765 | 0.021    |  |  |  |
| Severe lesion calcification | 4.242               | 2.074-8.677 | < 0.0001 |  |  |  |
| mult                        | tivariate anal      | ysis        |          |  |  |  |
|                             | OR                  | CI          | p-value  |  |  |  |
| Severe lesion calcification | 2.711               | 1.188-6.185 | 0.018    |  |  |  |
| Sex                         | 0.302               | 0.155-0.590 | < 0.0001 |  |  |  |
| BMI                         | 1.807               | 1.084-3.012 | 0.023    |  |  |  |
|                             |                     |             |          |  |  |  |

# Summary

- Japanese experts frequently chose the bidirectional approach as the primary strategy (27.9%), especially for more complex CTO lesions, with a technical success rate of about 90%.
- For intermediate CTO lesions (J-CTO score < 2), experts mainly performed the antegrade approach alone, with a very high success rate (more than 95%).
- However, for RBA, the success rate decreased to less than 80%.
   The experts frequently used the parallel wiring and IVUS-guided penetration in antegrade approach, with high technical success (75.0%–88.9%).
  - Severe lesion calcification was a strong predictor of failure.

#### Conclusion

CTO-PCI performed by highly experienced experts achieved a high technical success rate and a low rate of major complications.

# 18<sup>th</sup> CTO Club



#### June 2-3, 2017, Nagoya, Japan

#### www.cct.gr.jp/ctoclub